BEAM-101在治疗严重的镰状细胞疾病方面取得了积极的成果。 Beam Therapeutics reports positive results for BEAM-101 in treating severe sickle cell disease.

Beam治疗学分享了BEACON对BEAM-101试验的有希望的数据,BEAM-101是治疗严重镰状细胞疾病的可能办法。 Beam Therapeutics shared promising data from its BEACON trial for BEAM-101, a potential treatment for severe sickle cell disease. 7名病人的胎儿血红蛋白水平大幅上升,镰状血红蛋白水平下降,没有进行血管隔离危机的后期治疗。 Seven patients showed significant increases in fetal hemoglobin levels and decreases in sickle hemoglobin, with no vaso-occlusive crises post-treatment. 该疗法的安全情况符合标准治疗方法,超过35名病人参加了试验。 The therapy's safety profile aligns with standard treatments, and over 35 patients have enrolled in the trial.